Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center
Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla, Victor Castro-Oliden · 2024
Read Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center by Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla, Victor Castro-Oliden (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11577364.txt.
Description
Wagner Eduardo Cruz-Diaz and co-authors review a two drug oral regimen as first care for advanced gut and pancreas hormone tumors at a Peru center, in a study from 2024. Proof for the pair came mostly from richer lands, with Peru data scarce.
Thirty eight patients took the pair over a decade, most as their first care. Belly pain was the top sign at entry, and rectal and pancreas tumors led the sites. Survival at one, three, and five years fell step by step, with a mid point near four years. The authors back the pair as a sound choice for their setting.
Catalog record
| CREATOR | Wagner Eduardo Cruz-Diaz, Victor Paitan, Jersinho Medina, Raymundo Flores, Juan Haro-Varas, Raul Mantilla, Victor Castro-Oliden |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 21 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |